Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group. — Vasilios Karavasilis (2014) | RDL Network
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
Article 2014 en
Authors
VK
Vasilios Karavasilis
PK
P. Kosmidis
KS
Konstantinos N. Syrigos
Abstract
1 min read
Intermittent administration of erlotinib does not appear to improve the clinical outcome of single-agent docetaxel chemotherapy in unselected patients with NSCLC in the first-line setting.
Vassilis Georgoulias, C. Kourousis, N. Androulakis, S. Kakolyris, Meletios A Dimopoulos, Demosthenes Bouros, C. Papadimitriou, Kostas Hatzakis, P. Heras, K. Kalbakis, Thanos Kotsakis, N. Vardakis, N. Meramveliotakis, Dora Hatzidaki
Vassilis Georgoulias, C. Kourousis, Stylianos Kakolyris, N. Androulakis, Meletios A Dimopoulos, E. Papadakis, Thanos Kotsakis, N. Vardakis, K. Kalbakis, N. Merambeliotakis, Dora Hatzidaki
Vassilis Georgoulias, Charalambos Kouroussis, N. Androulakis, S. Kakolyris, Meletios A Dimopoulos, E. Papadakis, Demosthenes Bouros, F Apostolopoulou, Christos Papadimitriou, Athina Agelidou, Kostas Hatzakis, Kostas Kalbakis, Αthanasios Kotsakis, N. Vardakis, J. Vlachonicolis
Miguel A. Villalona‐Calero, Everett E. Vokes, Marzia Capelletti, Pasi A. Jänne, Martin J. Edelman, Jeffrey Crawford, Xiaofei Wang, Robert A. Kratzke, Thomas E. Stinchcombe, Lin Gu, Mark A. Socinski, Vincent A. Miller
Discussion(0)
No comments yet. Be the first to comment.